PGNY - NASDAQ

Progyny, Inc.

PGNY·NASDAQ

$24.99

-4.6%

HealthcareMedical - Healthcare Information Services

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.96B

EPS0.6800

P/E Ratio36.75

Earnings Date08/06/2026

742.43M

Assets

22%

3Y+37.0%

5Y+192.0%

10Y+2024.0%

226.39M

Total Liabilities

22%

3Y+36.0%

5Y+160.0%

10Y+833.0%

516.04M

Total Equity

22%

3Y+37.0%

5Y+209.0%

10Y+4727.0%

Progyny, Inc. Funding & Solvency Profile

PGNY · NASDAQ

Current Assets

Cash & Cash Equivalents112.24M

Net Receivables220.29M

Inventory0.00

Other Current Assets21.39M

Total Current Assets552 M

Non-Current Assets

Property, Plant & Equipment54.92M

Goodwill & Intangible Assets26.19M

Long-Term Investments0.00

Other Non-Current Assets16.54M

Total Non-Current Assets71 M

Total Assets

742.43M

Financial Health Analysis

Current Ratio

2.73x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.44x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

349 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

74% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Progyny, Inc. Balance Sheet

PGNY • NASDAQ

Progyny, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	112.2M	162.3M	97.3M	120.1M	91.4M	70.3M	80.4M	127K	4.7M
Short-Term Investments	197.9M	65.6M	273.8M	69.2M	28M	39M	0.0	0.0	0.0
Cash & Short-Term Investments	310.1M	228M	371.1M	189.3M	119.4M	109.3M	80.4M	127K	4.7M
Net Receivables	220.3M	235.3M	241.9M	240.1M	134.6M	75.7M	47.1M	23.3M	11.4M
Accounts Receivables	220.3M	235.3M	241.9M	240.1M	134.6M	75.7M	47.1M	23.3M	11.4M
Prepaids	0.0	0.0	0.0	0.0	4.6M	5.3M	5M	885K	706K
Other Current Assets	21.4M	9.4M	27.5M	4.5M	0.0	0.0	0.0	200K	0.0
Total Current Assets	551.8M	472.7M	640.4M	433.9M	258.5M	190.2M	132.4M	24.5M	16.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	54.9M	29.6M	27.8M	15.3M	12.8M	12.1M	3.1M	776K	597K
Goodwill	20M	15.5M	11.9M	11.9M	11.9M	11.9M	11.9M	11.9M	11.9M
Intangible Assets	6.2M	1.3M	0.0	99K	599K	1.2M	2.4M	3.9M	5.3M
Goodwill & Intangible Assets	26.2M	16.8M	11.9M	12M	12.5M	13.1M	14.3M	15.7M	17.2M
Tax Assets	93M	84.9M	73.1M	77.9M	71.3M	38M	0.0	0.0	0.0
Other Non-Current Assets	16.5M	3M	3.4M	4M	2.9M	573K	652K	272K	372K
Total Non-Current Assets	190.7M	134.4M	116.2M	109.1M	99.5M	63.7M	18M	16.8M	18.2M
Total Assets	742.4M	607.1M	756.6M	543M	358.1M	253.9M	150.4M	41.3M	35M
LIABILITIES
CURRENT LIABILITIES
Total Payables	124.1M	127.2M	155.7M	140.4M	81.4M	66.3M	19.4M	15.6M	5.1M
Accounts Payable	124.1M	95.1M	125.4M	109.3M	61.4M	43.5M	19.4M	15.6M	5.1M
Other Payables	0.0	32.1M	30.3M	31.1M	20M	22.8M	0.0	0.0	0.0
Accrued Expenses	0.0	18.7M	15M	9M	3.9M	2.6M	3.8M	2.7M	2.4M
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	253K	3.6M
Capital Lease Obligations (Current)	0.0	2.9M	2.1M	1.2M	1.2M	1.2M	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.4M	7.1M
Other Current Liabilities	78.3M	19.9M	13.1M	8.9M	12.3M	7.7M	13M	11.6M	6.7M
Total Current Liabilities	202.4M	168.6M	186M	159.5M	98.8M	77.8M	36.2M	30.2M	17.8M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6M
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	876K	0.0	0.0	4.9M
Total Non-Current Liabilities	24M	16.4M	17.2M	6.5M	7.4M	9.2M	0.0	106.2M	6.5M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-106.2M	0.0
Capital Lease Obligations	24M	19.3M	19.4M	7.7M	8.7M	9.5M	0.0	0.0	0.0
Total Liabilities	226.4M	185M	203.2M	166M	106.2M	87M	36.2M	30.2M	24.3M
SHAREHOLDERS' EQUITY
Treasury Stock	-388.1M	-303.9M	-1M	-1M	-1M	-1M	-1M	-884K	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	150.4M	106.2M	108.3M
Common Stock	9K	9K	9K	9K	9K	9K	8K	1K	1K
Additional Paid-In Capital	700.8M	581.6M	461.6M	349.5M	255.3M	236.1M	228.8M	10.6M	6.9M
Retained Earnings	202.8M	144.3M	90M	27.9M	-2.4M	-68.2M	-113.5M	-104.9M	-104.6M
Accumulated Other Comprehensive Income/Loss	498K	39K	2.8M	501K	-93K	1K	-150.4M	-483K	-83K
Total Stockholders' Equity	516M	422.1M	553.4M	377M	251.8M	166.9M	114.3M	11.1M	10.7M
Total Equity	516M	422.1M	553.4M	377M	251.8M	166.9M	114.3M	11.1M	10.7M
SUMMARY
Total Liabilities & Equity	742.4M	607.1M	756.6M	543M	358.1M	253.9M	150.4M	41.3M	35M
Total Investments	197.9M	65.6M	273.8M	69.2M	28M	39M	0.0	0.0	0.0
Total Debt	24M	19.3M	19.4M	7.7M	8.7M	9.5M	0.0	253K	5.2M
Net Debt	-88.2M	-143M	-77.9M	-112.4M	-82.8M	-60.8M	-80.4M	126K	497K
Shares Outstanding	85,982,400	85,982,400	85,982,400	85,982,400	85,982,400	85,982,400	85,982,400	85,982,400	85,982,400

SEC Filings

PGNY - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 27, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 26, 2026	May 26, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 08, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 10, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 13, 2026	January 26, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 27, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 17, 2025	December 12, 2025	2025	View Filing

Showing 1 to 10 of 94 filings

Related Guides

Blog Categories

Continue your PGNY research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.